Angiotensin II Increases Vascular and Renal Endothelin-1 and Functional Endothelin Converting Enzyme Activityin Vivo:Role of ETAReceptors for Endothelin Regulation

doi:10.1006/bbrc.1997.7394

Biochemical and Biophysical Research Communications

Volume 238, Issue 3, 29 September 1997, Pages 861-865

https://doi.org/10.1006/bbrc.1997.7394 Get rights and content

Abstract

Angiotensin II (Ang II)-stimulated expression of endothelin-1 (ET-1) mRNA is blocked by ET_Aantagonistsin vitro.We studied effects of Ang II (200 ng/kg/min) and ET_Aantagonist LU135252 (50 mg/kg/d) in WKY ratsin vivoinvestigating vascular and renal ET-1 protein expression, functional endothelin converting enzyme (ECE) activity, and clearance of^125IET-1. Infusion of Ang II for two weeks increased ET-1 protein content in aorta (4.7-fold) and femoral artery (1.6-fold) with and without endothelium and in kidneys (3-fold, p<0.05) and enhanced functional ECE activity (p<0.05). The Ang II-induced increase in tissue ET-1 content and functional ECE activity was completely prevented by LU135252 (p<0.05). Chronic treatment of control animals with LU135252 lowered basal vascular but not renal ET-1 content (p<0.05 vs. control). Clearance of^125IET-1 was unaffected by the treatments. It is concluded that Ang II increases ET-1 protein and functional ECE activity in vascular smooth muscle and kidney through ET_A-receptorsin vivo.

References (28)

G.F. Alberts et al.
J. Biol. Chem.
(1994)
D. Xu et al.
Cell
(1994)
M. Takahashi et al.
J. Biol. Chem.
(1993)
K. Ohnaka et al.
J. Biol. Chem.
(1993)
E. Lawrence et al.
Eur. J. Pharmacol.
(1993)
C.R. Gandhi
Biochim. Biophys. Acta
(1995)
T. Fukuroda et al.
Biochem. Biophys. Res. Commun.
(1994)
O.F. Wagner et al.
J. Biol. Chem.
(1992)
M. Yanagisawa et al.
Nature
(1988)
Y. Dohi et al.
Hypertension
(1992)

A.W. Hahn et al.

Cell Regul.

(1990)

H. Fujisaki et al.

J. Clin. Invest.

(1995)

K. Hisaki et al.

Am. J. Physiol.

(1996)

Cited by (185)

The endothelin system as target for therapeutic interventions in cardiovascular and renal disease
2020, Clinica Chimica Acta
Endothelins including its most abundant isoform, endothelin-1 (ET-1), are peptides acting as vasoconstrictors when binding to ET_A and ET_B receptors, and, in addition to their distinct roles in normal physiology, endothelins have a central role in the pathophysiology of many diseases including cardiovascular and renal diseases. Endothelin-1 (ET-1), the most potent vasoconstrictor in the cardiovascular system, regulates basal vascular tone and glomerular hemodynamics. ET-1 is involved also in vascular and cardiac hypertrophy, inflammation, and in the development and progression of cardiovascular diseases - e.g. essential hypertension, atherosclerosis, coronary artery disease, congestive heart failure, pulmonary arterial hypertension and cerebrovascular disease and renal diseases - e.g. acute renal failure, polycystic kidney disease and chronic kidney disease. Not surprisingly, the ET system has become a target for therapeutic interventions that now include a few already established and some new promising agents. In this narrative review, we summarize physiologic properties of the ET system, focusing especially on ET-1, and its role in the pathophysiology of ET system activated diseases, and discuss the potentials of therapeutic interventions targeting the ET system in cardiovascular and renal diseases. While ET receptor antagonists have already revolutionized the management of idiopathic pulmonary arterial hypertension, so far, this class of drugs have failed as medication for congestive heart failure. Clinical trials continue to explore new applications of endothelin receptor antagonists in treatment-resistant hypertension and chronic kidney disease and have shown some benefits in the latter group by reducing proteinuria; however, they have not been approved yet. We conclude that larger clinical trials are needed to validate the use of ET receptor antagonists in ET system activated diseases.
Nox1 downregulators: A new class of therapeutics
2019, Steroids
Citation Excerpt :
In renal medicine, a main therapeutic goal is slow the progression of proteinuria and chronic renal disease, they are predominantly inhibitors of the renin-angiotensin-system, its main effector angiotensin II being a key activator of Nox1 [102]. Angiotensin II leads to activation of inflammation- and proliferation-propagating pathways, such as the endothelin system, not only in the vasculature but also in the kidney [103]. Importantly, Nox1 directly contributes to angiotensin II-induced ROS-mediated aldosterone synthesis in human and rat adrenal cells, an effect that can be abrogated by silencing the Nox1 gene [103].
Chronic non-communicable diseases share the pathomechanism of increased reactive oxygen species (ROS) production by nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, known as Nox. The recent discovery that expression of Nox1, a Nox isoform that has been implicated in the pathogenesis of cardiovascular and kidney disease and cancer is regulated by the expression and activity of G protein-coupled estrogen receptor (GPER) led to the identification of orally active small-molecule GPER blockers as selective Nox1 downregulators (NDRs). Preclinical studies using NDRs have demonstrated beneficial effects in vascular disease, hypertension, and glomerular renal injury. These findings suggest the therapeutic potential of NDRs, which reduce Nox1 protein levels, not only for cardiovascular disease conditions including arterial hypertension, pulmonary hypertension, heart failure with preserved ejection fraction (HFpEF), and chronic renal disease, but also for other non-communicable diseases, such as cerebrovascular disease and vascular dementia, Alzheimer's disease, autoimmune diseases and cancer, in which elevated Nox1-derived ROS production plays a causal role.
Cardiorenal Syndrome: Pathophysiology
2019, Cardiology Clinics
New pharmacological strategies for protecting kidney function in type 2 diabetes
2019, The Lancet Diabetes and Endocrinology
Type 2 diabetes is the leading cause of impaired kidney function, albuminuria, and renal replacement therapy globally, thus placing a large burden on health-care systems. Current treatment strategies rely on intensive glucose lowering as well as strict blood pressure control through blockade of the renin–angiotensin–aldosterone system. Such approaches might slow decline in kidney function, but many patients progress to end-stage kidney failure despite optimal therapy. In recent clinical trials, new-generation glucose-lowering drug classes, the sodium-glucose co-transporter-2 inhibitors and agents that target the incretin pathway, have been shown to improve kidney outcomes in patients with type 2 diabetes. Other new approaches, which have been developed on the basis of an improved understanding of the mechanisms that contribute to kidney damage in the context of diabetes, include use of drugs that block endothelin receptors (eg, atrasentan) and non-steroidal mineralocorticoid receptors (eg, finerenone). In this Review, we provide an overview of recent clinical data relevant to these new therapeutic approaches for management of kidney disease in the context of type 2 diabetes.
Pharmacological Induction of Kidney Regeneration
2017, Kidney Transplantation, Bioengineering, and Regeneration: Kidney Transplantation in the Regenerative Medicine Era
The incidence of kidney disease is increasing worldwide, becoming one of the major public health problems. Until recently, the kidney was considered an organ with a limited capacity for repair and the progression to end-stage renal disease has generally been considered inexorable. Technological advances in the field of three-dimensional visualization of organ ultrastructure made in recent decades, together with the identification of renal progenitor cells lining the Bowman’s capsule of adult rat and human kidneys, have allowed to prove that tissue repair in the adult kidney is possible, even in mammals. Experimental and clinical studies that aim to identify drugs capable to influence renal progenitors fate and/or interfere with the pathogenetic pathways underlying renal disease progression have great potential for future kidney regeneration.
Metabolic acidosis in chronic kidney disease: mere consequence or also culprit?
2024, Pflugers Archiv European Journal of Physiology

View all citing articles on Scopus

View full text

Regular ArticleAngiotensin II Increases Vascular and Renal Endothelin-1 and Functional Endothelin Converting Enzyme Activityin Vivo:Role of ETAReceptors for Endothelin Regulation

Abstract

J. Biol. Chem.

Cell

J. Biol. Chem.

J. Biol. Chem.

Eur. J. Pharmacol.

Biochim. Biophys. Acta

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

Nature

Hypertension

Cell Regul.

J. Clin. Invest.

Am. J. Physiol.

Regular Article
Angiotensin II Increases Vascular and Renal Endothelin-1 and Functional Endothelin Converting Enzyme Activityin Vivo:Role of ET_AReceptors for Endothelin Regulation